FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1524 October 6, 2005 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Abrams, J. PubMed Citation

To the Editor: In his Clinical Practice article (June 16 issue),¹ Abrams suggests that a 24-hour interval is warranted between the use of the phosphodiesterase inhibitors sildenafil, vardenafil, and tadalafil and the use of nitrates to prevent serious hypotension. However, Kloner² differentiates among agents, recommending a 24-hour interval in the case of sildenafil or vardenafil, but at least 48 hours in the case of tadalafil.³

Under the heading "Areas of Uncertainty," Abrams questioned the role of ranolazine in the treatment of stable angina. There are at least two trials in which ranolazine is evaluated in this setting. In the Monotherapy . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.